Evaluation of fetomaternal outcomes and serum analytes in placenta previa and associated placenta accreta spectrum
Year: 2025
Type: article
Study design: Observational Study
Abstract: Aims: Evaluation of fetomaternal outcomes and serum analytes values in patients with placenta previa and associated placenta accreta spectrum ( PAS). Methods: The study comprised 160 patients, of whom 74 (46.3%) had placenta previa, 28 (17.5%) had PAS, and 58 (36.3%) were pregnant women in a healthy condition. The diagnosis was suspected by ultrasound examination and confirmed by the intraoperative findings and the pathology report. Demographic and obstetric characteristics data of the pregnant women, maternal and fetal outcomes, screening tests for the first and second trimester results of serum analysis were obtained retrospectively from the hospital records. The significance threshold was set at p<0.05 using the IBM SPSS.25 software. Results: The mean age was significantly higher in the previa and PAS groups. The groups differed significantly in terms of the history of prior cesarean deliveries and gestational age at delivery. The PAS group had the lowest APGAR score and the lowest newborn weight (p<.001). Compared to the PAS group, the previa group's PAPP-A (pregnancy associated plasma protein-A) Mom value was considerably greater (p=.008). The AFP (alpha-fetoprotein) Mom value was significantly higher in the group of healthy pregnant women than in the group of previa (p=.015). Compared to the previa (p=.008) and PAS (p=.024) groups, the healthy pregnant group's UE3 (Unconjugated Estriol-3) Mom value was much higher. Conclusion: Although the obstetric, fetal and maternal outcomes in our study were consistent with the literature, the serum analysis results were not.
DOI: 10.51271/jcogp-0049
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4412371722